Wordt geladen...
Clinical Impact of Revised Ciprofloxacin Breakpoint in Patients with Urinary Tract Infections by Enterobacteriaceae
In 2018, the Clinical and Laboratory Standards Institute (CLSI) revised ciprofloxacin (CIP)-susceptible breakpoint for Enterobacteriaceae from ≤1 μg/mL to ≤0.25 μg/mL, based on pharmacokinetic-pharmacodynamic (PK-PD) analysis. However, clinical data supporting the lowered CIP breakpoint are insuffic...
Bewaard in:
| Gepubliceerd in: | Antibiotics (Basel) |
|---|---|
| Hoofdauteurs: | , , , , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
MDPI
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8074352/ https://ncbi.nlm.nih.gov/pubmed/33924153 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/antibiotics10040469 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|